Herceptin (trastuzumab) now offers a significant new approach for treating metastatic breast cancer
September 1999
The recent approval of Herceptin (trastuzumab) now offers a significant new approach for treating metastatic breast cancer.
Herceptin is the first monoclonal antibody for breast cancer.
It targets HER2...a protein that stimulates the growth of breast cancer cells. This type of breast cancer tends to be more aggressive and leads to shorter survival.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive